MedTrace Logo

Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus

NCT03276039 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2017-09-08

No results posted yet for this study

Summary

This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.

Conditions

  • Non Alcoholic Fatty Liver Disease

Interventions

DIAGNOSTIC_TEST

plasma pentraxin-3

Plasma pentraxin-3 was measured using ELISA

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-15
Primary Completion
2016-04-15
Completion
2016-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03276039 on ClinicalTrials.gov